This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies.
Despite falling business interest in environmental, social and governance polici...
Despite falling business interest in environmental, social and governance polici...
On Monday, Delaware’s state investment board approved a $30.2 million grant to M...
As part of a new strategic restructuring to streamline its American operations, ...
With sales of $103 million in the fourth quarter and $180 million in its first n...
With sales of $103 million in the fourth quarter and $180 million in its first n...
On BeiGene’s very first live earnings call, CEO and co-founder John Oyler descri...
After receiving a rare pediatric disease priority review voucher in tandem with ...
Disruptions to government-sanctioned advisory committee meetings on vaccines are...
In this tracker, Fierce Pharma is recording the regulatory progress of in-market...
More than a decade after earning FDA approval for Xiaflex as a nonsurgical treat...
More than a decade after earning FDA approval for Xiaflex as a nonsurgical treat...
Arnie told us he’d be back. Three months after becoming Zimmer Biomet’s chief mo...
The government price negotiations affecting Keytruda wouldn't take effect until ...
Merely a minute into his prepared remarks during Jazz Pharmaceuticals’ fourth-qu...
Following an inspection of Piramal’s production facility in Maharashtra, India, ...
At a press conference in Washington, D.C. dubbed “Lilly in America,” the Indiana...
At a press conference in Washington, D.C. dubbed “Lilly in America,” the Indiana...
Blood test maker Grail has recruited ‘Grey’s Anatomy’ star Kate Walsh to join a ...
The company is adding higher-dose Zepbound options to its online pharmacy and tr...
Compounding pharmacies aren’t surrendering their ability to create cheaper knock...
Blood test maker Grail has recruited ‘Grey’s Anatomy’ star Kate Walsh to join a ...
On the heels of a move to reduce its viral vector manufacturing workforce, Therm...
As Stelara biosimilars gradually make their way on to the U.S. market, Johnson &...